Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Boehringer Ingelheim, NCC Forge Comprehensive Partnership
July 12, 2017
- Daiichi Sankyo’s Oncolytic Virus Gets Orphan Status
July 12, 2017
- Ethical Drug Sales Tick Up 1.7% in May: Crecon
July 12, 2017
- Mundipharma Inks Partnership with J1 Soccer Team, Isodine Logo Put on Uniform
July 11, 2017
- Takeda’s Drug Discovery Support Subsidiary Now Up and Running
July 11, 2017
- Chugai, Osaka Univ. Immunology Collaboration Gets Underway
July 11, 2017
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
- Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact
July 10, 2017
- Boxed Warning Erased for Pfizer Smoking Cessation Aid Champix
July 10, 2017
- MSD, Bayer Yakuhin to Comarket Zetia-Statin Combo Drugs
July 10, 2017
- Maruho Takes Over Marketing Authorization for Astellas’ Protopic Ointment
July 10, 2017
- RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO
July 10, 2017
- Konica Minolta Buying US Diagnostics Firm to Fully Enter Precision Medicine Biz
July 7, 2017
- Nippon Chemiphar Sounds Positive about Authorized Generic Biz
July 7, 2017
- Shire Japan Files Hereditary Angioedema Drug Icatibant
July 7, 2017
- AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race
July 7, 2017
- Meiji Seika Pharma Launches 1st AG with Meiact Generic
July 6, 2017
- Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations
July 6, 2017
- Daiichi Sankyo Drops Enbrel Biosimilar Development in Japan
July 6, 2017
- Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen
July 5, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…